US6972193B1
(en)
*
|
1993-02-12 |
2005-12-06 |
Board Of Trustees Of Leland Stanford Junior University |
Regulated transcription of targeted genes and other biological events
|
US6891021B2
(en)
*
|
1993-02-12 |
2005-05-10 |
Board Of Trustees Of The Leland Stanford Junior University |
Regulated apoptosis
|
US5589362A
(en)
*
|
1993-06-14 |
1996-12-31 |
Basf Aktiengesellschaft |
Tetracycline regulated transcriptional modulators with altered DNA binding specificities
|
US5912411A
(en)
*
|
1993-06-14 |
1999-06-15 |
University Of Heidelberg |
Mice transgenic for a tetracycline-inducible transcriptional activator
|
US5814618A
(en)
*
|
1993-06-14 |
1998-09-29 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
AU684524B2
(en)
*
|
1993-06-14 |
1997-12-18 |
Tet Systems Holding Gmbh & Co. Kg |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
US6004941A
(en)
*
|
1993-06-14 |
1999-12-21 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
US5866755A
(en)
*
|
1993-06-14 |
1999-02-02 |
Basf Aktiengellschaft |
Animals transgenic for a tetracycline-regulated transcriptional inhibitor
|
US5654168A
(en)
*
|
1994-07-01 |
1997-08-05 |
Basf Aktiengesellschaft |
Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
|
US5789156A
(en)
*
|
1993-06-14 |
1998-08-04 |
Basf Ag |
Tetracycline-regulated transcriptional inhibitors
|
US5888981A
(en)
*
|
1993-06-14 |
1999-03-30 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
US5859310A
(en)
*
|
1993-06-14 |
1999-01-12 |
Basf Aktiengesellschaft |
Mice transgenic for a tetracycline-controlled transcriptional activator
|
CN1130401A
(zh)
*
|
1993-07-16 |
1996-09-04 |
莱兰斯坦福初级大学评议会 |
被调节的细胞程序死亡
|
US20030036654A1
(en)
|
1994-08-18 |
2003-02-20 |
Holt Dennis A. |
Synthetic multimerizing agents
|
US6150527A
(en)
*
|
1994-08-18 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Synthetic multimerizing agents
|
WO1996006111A1
(en)
*
|
1994-08-18 |
1996-02-29 |
Ariad Gene Therapeutics, Inc. |
Regulatable elimination of gene expression, gene product function and engineered host cells
|
US6133456A
(en)
*
|
1994-08-18 |
2000-10-17 |
Ariad Gene Therapeutics, Inc. |
Synthetic multimerizing agents
|
ATE299145T1
(de)
*
|
1994-08-18 |
2005-07-15 |
Ariad Gene Therapeutics Inc |
Neues multimerisierendes reagenz
|
EP0785992A4
(de)
*
|
1994-10-25 |
1999-12-22 |
Univ Leland Stanford Junior |
Die abhängige transformation von genetisch manipulierten zellen
|
GB9425600D0
(en)
*
|
1994-12-19 |
1995-02-15 |
Medical Res Council |
Targeting complexes and use thereof
|
US6326166B1
(en)
*
|
1995-12-29 |
2001-12-04 |
Massachusetts Institute Of Technology |
Chimeric DNA-binding proteins
|
EP0805819B1
(de)
|
1994-12-29 |
2012-02-08 |
Massachusetts Institute Of Technology |
Chimäre dna-bindeproteine
|
US5741899A
(en)
*
|
1995-02-02 |
1998-04-21 |
Cell Genesys, Inc. |
Chimeric receptors comprising janus kinase for regulating cellular pro liferation
|
US6103521A
(en)
*
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
US6060238A
(en)
*
|
1995-02-13 |
2000-05-09 |
The Regents Of The University Of Michigan |
Method and composition for regulating apoptosis
|
US6015665A
(en)
*
|
1995-02-13 |
2000-01-18 |
The Regents Of The University Of Michigan |
Method and composition for regulating apoptosis
|
US7097972B1
(en)
|
1995-02-13 |
2006-08-29 |
Regents Of The University Of Michigan |
Method and composition for regulating apoptosis
|
US6747138B1
(en)
*
|
1995-04-03 |
2004-06-08 |
Regents Of The University Of Michigan |
Methods and compositions for regulating Fas-associated apoptosis
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
CA2219080A1
(en)
*
|
1995-06-07 |
1996-12-27 |
Ariad Gene Therapeutics, Inc. |
Rapamycin-based regulation of biological events
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
DE19545351C1
(de)
*
|
1995-12-05 |
1997-07-31 |
Univ Ludwigs Albert |
Eukaryotische Zellen mit Hybridrezeptor und dadurch steuerbarem Genkonstrukt, Verfahren zu deren Herstellung und Verwendung dieser Zellen in der Gentherapie
|
CA2244363C
(en)
*
|
1996-02-28 |
2006-11-14 |
Ariad Gene Therapeutics, Inc. |
Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
|
DE69715621T2
(de)
*
|
1996-04-26 |
2003-05-22 |
Massachusetts Inst Technology |
Drei hybriden screening test
|
US6630346B1
(en)
|
1996-06-20 |
2003-10-07 |
Merck & Co., Inc. |
Gene therapy for obesity
|
WO1998026066A1
(en)
*
|
1996-12-09 |
1998-06-18 |
Ariad Gene Therapeutics, Inc. |
Expression of proteins for treating asthma via ligand mediated activation of their encoding genes
|
AU6692298A
(en)
*
|
1997-03-07 |
1998-09-22 |
Ariad Gene Therapeutics, Inc. |
New applications of gene therapy technology
|
US6982082B1
(en)
|
1997-08-27 |
2006-01-03 |
President And Fellows Of Harvard College |
Gene therapy by cell specific targeting
|
US20030220234A1
(en)
*
|
1998-11-02 |
2003-11-27 |
Selvaraj Naicker |
Deuterated cyclosporine analogs and their use as immunodulating agents
|
US6153383A
(en)
*
|
1997-12-09 |
2000-11-28 |
Verdine; Gregory L. |
Synthetic transcriptional modulators and uses thereof
|
US7754202B1
(en)
*
|
1998-01-08 |
2010-07-13 |
Stanford University |
Methods of controlling cell differentiation and growth using a fusion protein and a drug
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
ES2347027T3
(es)
|
1998-05-22 |
2010-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Moleculas bifuncionales y terapias basadas en las mismas.
|
IL142138A0
(en)
*
|
1998-10-19 |
2002-03-10 |
Ariad Gene Therapeutics Inc |
Materials and methods involving conditional aggregation domains
|
CA2346962A1
(en)
*
|
1998-11-06 |
2000-05-18 |
President And Fellows Of Harvard College |
Fk506-based regulation of biological events
|
US7109317B1
(en)
|
1998-11-06 |
2006-09-19 |
President And Fellows Of Harvard College |
FK506-based regulation of biological events
|
DE19907598A1
(de)
*
|
1999-02-22 |
2000-08-24 |
Schulz Burkhard |
DNA Sequenz kodierend ein FKBP ähnliches Protein, Plasmide, Bakterien, Hefen und Pflanzen enthaltend dieses Protein sowie Mutanten in Arabidopsis für dieses Gen, die in der Ausprägung der Pflanzenarchitektur, der Reaktion gegenüber Brassinosteroiden und ihren Verbindungen und durch Ethylen vermittelten Gravitropismus der Wurzel defekt sind
|
US20030215423A1
(en)
*
|
1999-04-01 |
2003-11-20 |
Merck & Co., Inc. |
Gene therapy for obesity
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
WO2001036612A1
(en)
*
|
1999-11-19 |
2001-05-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and their use in the disruption of protein-protein interactions
|
US7220552B1
(en)
|
1999-11-19 |
2007-05-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and their use in the disruption of protein-protein interactions
|
US7498025B1
(en)
|
1999-11-19 |
2009-03-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeted bifunctional molecules and therapies based thereon
|
US6887842B1
(en)
|
1999-11-19 |
2005-05-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
|
AU784883B2
(en)
|
1999-12-30 |
2006-07-20 |
President And Fellows Of Harvard College |
Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
|
US7541184B2
(en)
*
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
AU8178401A
(en)
|
2000-05-22 |
2001-12-03 |
Vlaams Interuniv Inst Biotech |
Receptor-based interaction trap
|
US7323174B1
(en)
|
2000-06-12 |
2008-01-29 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Modulation of immune response and methods based thereon
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
EP1975620A3
(de)
|
2001-03-02 |
2008-12-24 |
GPC Biotech AG |
Dreihybrid-Testsystem
|
MXPA03008959A
(es)
|
2001-04-02 |
2004-10-15 |
Wyeth Corp |
Pd-1, un receptor para b7-4 y sus usos.
|
GB0112126D0
(en)
*
|
2001-05-18 |
2001-07-11 |
Allergene Inc |
Composition
|
PL210795B1
(pl)
|
2001-10-19 |
2012-03-30 |
Isotechnika Inc |
Sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (E), sposób wytwarzania mieszaniny ISATX247 wzbogaconej w izomer (Z), sposób stereoselektywnej syntezy izomeru (E) ISATX247, sposób stereoselektywnej syntezy izomeru (Z) ISATX247 i sposób wytwarzania mieszaniny izomerów ISATX247
|
PT2308888T
(pt)
|
2001-11-14 |
2017-05-03 |
Janssen Biotech Inc |
Anticorpos anti-il-6, composições, métodos e utilizações
|
US20030144204A1
(en)
*
|
2001-12-19 |
2003-07-31 |
Baylor College Of Medicine |
Akt-based inducible survival switch
|
US6635892B2
(en)
*
|
2002-01-24 |
2003-10-21 |
Pei Electronics, Inc. |
Compact integrated infrared scene projector
|
KR101004224B1
(ko)
|
2002-02-01 |
2010-12-27 |
어리어드 파마슈티칼스, 인코포레이티드 |
인 함유 화합물 및 이의 용도
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
AU2003280130B2
(en)
|
2002-06-28 |
2009-06-11 |
Centocor, Inc. |
Mammalian CH1 deleted mimetibodies, compositions, methods and uses
|
WO2004003142A2
(en)
*
|
2002-06-28 |
2004-01-08 |
Xcyte Therapies, Inc. |
Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
US20040175373A1
(en)
*
|
2002-06-28 |
2004-09-09 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
EP2557164A1
(de)
|
2003-02-18 |
2013-02-13 |
Kevin M. Slawin |
Induzierte Aktivierung ein dendritischen Zellen
|
US20050014680A1
(en)
*
|
2003-04-15 |
2005-01-20 |
Crabtree Gerald R. |
Methods and compositions for enhancing neuron growth and survival
|
CN101052726A
(zh)
|
2003-05-09 |
2007-10-10 |
森托科尔公司 |
IL-23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
US20050171015A1
(en)
*
|
2003-10-31 |
2005-08-04 |
Crabtree Gerald R. |
Methods and agents for enhancing bone formation or preventing bone loss
|
EP1723239B1
(de)
|
2004-02-09 |
2009-12-09 |
Synamem Corporation |
Verfahren zur erzeugung verankerter proteine
|
KR20070004078A
(ko)
*
|
2004-03-31 |
2007-01-05 |
센토코 인코포레이티드 |
인간 glp-1 모방체, 조성물, 방법 및 용도
|
US20050238628A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Blau Carl A |
Methods for treating cancer
|
US7968762B2
(en)
|
2004-07-13 |
2011-06-28 |
Van Andel Research Institute |
Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
|
US7393662B2
(en)
*
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
WO2006069038A1
(en)
*
|
2004-12-20 |
2006-06-29 |
Ariad Gene Therapeutics, Inc. |
Therapeutic materials and methods
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
WO2007005955A2
(en)
|
2005-06-30 |
2007-01-11 |
Centocor, Inc. |
Anti-il-23 antibodies, compositions, methods and uses
|
EA035459B1
(ru)
|
2005-12-29 |
2020-06-19 |
Сентокор, Инк. |
Антитело против il-23p19
|
EP2535426A3
(de)
|
2006-03-02 |
2013-07-24 |
The Uab Research Foundation |
Erkennung und Behandlung von, sowie Entdeckung von Heilmitteln gegen Mycobakterielle Krankheiten
|
EP2007602A4
(de)
*
|
2006-03-31 |
2010-09-22 |
Centocor Ortho Biotech Inc |
Humane mimetische epo-hinge-core-mimetikörper, zusammensetzungen, verfahren und verwendung zur prävention oder behandlung von glukoseintoleranzbedingten erkrankungen oder mit nierenkrankheit assoziierter anämie
|
AU2007310946B2
(en)
*
|
2006-10-19 |
2014-06-05 |
Baylor College Of Medicine |
Generating an immune response by inducing CD40 and pattern recognition receptors
|
UY30820A1
(es)
*
|
2006-12-21 |
2008-07-03 |
Centocor Inc |
Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
CA2733642A1
(en)
|
2008-08-14 |
2010-02-18 |
Cephalon Australia Pty Ltd |
Anti-il-12/il-23 antibodies
|
EP2331680B1
(de)
*
|
2008-09-22 |
2017-05-03 |
Baylor College Of Medicine |
Verfahren und zusammensetzungen zur erzeugung einer immunreaktion mittels cd40-induktion sowie strukturerkennungsrezeptoradaptern
|
KR101781907B1
(ko)
|
2008-10-31 |
2017-09-26 |
얀센 바이오테크 인코포레이티드 |
파이브로넥틴 타입 ⅲ 도메인 기반 스캐폴드 조성물, 방법 및 용도
|
EP2396011B1
(de)
|
2009-02-12 |
2016-04-13 |
Janssen Biotech, Inc. |
Auf fibronectin-typ-iii-domain basierende gerüstzusammensetzungen, verfahren und anwendung
|
EP2258858A1
(de)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Für LSD1 transgenisches Tiermodell für Krebs
|
WO2011088163A1
(en)
|
2010-01-14 |
2011-07-21 |
President And Fellows Of Harvard College |
Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
US20130023033A1
(en)
|
2010-03-29 |
2013-01-24 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
EP4269563A3
(de)
|
2010-06-19 |
2024-01-10 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2-antikörper
|
WO2011163029A2
(en)
*
|
2010-06-21 |
2011-12-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Alkenyl substituted cycloaliphatic compounds as chemical inducers of proximity
|
WO2012051301A1
(en)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
|
WO2012109238A2
(en)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Methods for increasing immune responses using agents that directly bind to and activate ire-1
|
EP2699688A1
(de)
|
2011-04-20 |
2014-02-26 |
The Trustees Of The University Of Pennsylvania |
Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern
|
US10634668B2
(en)
*
|
2012-09-13 |
2020-04-28 |
Takara Bio Usa, Inc. |
Modifiable chemical inducers of proximity and methods of using the same
|
PT3613439T
(pt)
*
|
2013-02-15 |
2021-05-12 |
Univ California |
Recetor de antigénio quimérico e métodos de utilização do mesmo
|
US20140255403A1
(en)
|
2013-03-06 |
2014-09-11 |
Hadasit Medical Research Services & Development Ltd. |
Oral composition comprising a tnf antagonist and use thereof
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
CA2905352A1
(en)
|
2013-03-14 |
2014-09-25 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling t cell proliferation
|
EP2970426B1
(de)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Anzielung zytotoxischer zellen mit chimären rezeptoren für eine adoptive immuntherapie
|
JP6482525B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
高親和性抗gd2抗体
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
DK3004329T3
(da)
|
2013-06-05 |
2020-05-18 |
Bellicum Pharmaceuticals Inc |
Fremgangsmåder til induktion af delvis apoptose under anvendelse af caspasepolypeptider
|
US9593356B2
(en)
|
2013-06-11 |
2017-03-14 |
Takara Bio Usa, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
EP3925618A1
(de)
|
2013-07-29 |
2021-12-22 |
2seventy bio, Inc. |
Multilaterale signalisierungsproteine und verwendungen davon
|
EP3521431A1
(de)
|
2013-09-25 |
2019-08-07 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
EP3087101B1
(de)
*
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
JP6772063B2
(ja)
|
2014-02-14 |
2020-10-21 |
ベリカム ファーマシューティカルズ, インコーポレイテッド |
誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
|
WO2015127242A1
(en)
*
|
2014-02-21 |
2015-08-27 |
President And Fellows Of Harvard College |
De novo design of allosteric proteins
|
RU2751660C2
(ru)
|
2014-07-21 |
2021-07-15 |
Новартис Аг |
Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
|
CA2959168A1
(en)
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
JP6718444B2
(ja)
|
2014-11-03 |
2020-07-08 |
アカデミッシュ ザイケンホイス レイデン (エイチ.オー.ディー.エヌ. エルユーエムシー) |
Bob1に対して指向されるT細胞レセプターおよびその使用
|
KR102624023B1
(ko)
|
2015-02-24 |
2024-01-11 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
결합-촉발된 전사 스위치 및 이들의 이용 방법
|
IL296062A
(en)
|
2015-03-17 |
2022-10-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies against muc16 and their uses
|
US10441644B2
(en)
|
2015-05-05 |
2019-10-15 |
The Regents Of The University Of California |
H3.3 CTL peptides and uses thereof
|
WO2016200543A2
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
SG10201913805RA
(en)
|
2016-01-08 |
2020-03-30 |
Univ California |
Conditionally active heterodimeric polypeptides and methods of use thereof
|
JP7046828B2
(ja)
|
2016-04-15 |
2022-04-04 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
滲出型加齢性黄斑変性の治療のための組成物
|
CN109715670A
(zh)
|
2016-07-15 |
2019-05-03 |
波赛达治疗公司 |
对muc1特异性的嵌合抗原受体(car)及其使用方法
|
WO2018014038A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
AU2017378153B2
(en)
|
2016-12-13 |
2024-03-28 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
CA3051484A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
JP2020506947A
(ja)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
SG11201907714UA
(en)
|
2017-02-28 |
2019-09-27 |
Univ Pennsylvania |
Adeno-associated virus (aav) clade f vector and uses therefor
|
CA3052487A1
(en)
|
2017-02-28 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Influenza vaccines based on aav vectors
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
CN107488636A
(zh)
*
|
2017-09-30 |
2017-12-19 |
山东兴瑞生物科技有限公司 |
一种携带分子开关的抗her2嵌合抗原受体修饰的免疫细胞及其应用
|
WO2019079496A2
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio, Inc. |
FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION
|
EP3697449A1
(de)
|
2017-10-18 |
2020-08-26 |
REGENXBIO Inc. |
Behandlung von augenkrankheiten und metastasierendem dickdarmkrebs mit menschlicher post-translational modifizierter vegf-falle
|
WO2019118895A1
(en)
|
2017-12-14 |
2019-06-20 |
Bluebird Bio, Inc. |
Daric interleukin receptors
|
AU2018393110B2
(en)
|
2017-12-20 |
2023-04-27 |
Poseida Therapeutics, Inc. |
VCAR compositions and methods for use
|
AU2019260687B2
(en)
|
2018-04-27 |
2022-09-22 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
EP3790587A4
(de)
|
2018-05-11 |
2022-01-26 |
Janssen Biotech, Inc. |
Verfahren zur behandlung von depression mithilfe von il-23-antikörpern
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
US20220042038A1
(en)
|
2018-12-20 |
2022-02-10 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
EP3938391A1
(de)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Verfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
|
JP2022525179A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を産生するための産生方法
|
US20220153829A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
SG11202110789VA
(en)
|
2019-04-03 |
2021-10-28 |
Regenxbio Inc |
Gene therapy for eye pathologies
|
KR20220012231A
(ko)
|
2019-04-24 |
2022-02-03 |
리젠엑스바이오 인크. |
완전-인간 번역 후 변형된 항체 치료제
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
KR20220030952A
(ko)
|
2019-06-03 |
2022-03-11 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
WO2020245676A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
KR20220051246A
(ko)
|
2019-08-26 |
2022-04-26 |
리젠엑스바이오 인크. |
완전 인간 번역 후 변형된 항-VEGF Fab를 사용한 당뇨병성 망막병증의 치료
|
KR20220057596A
(ko)
|
2019-09-05 |
2022-05-09 |
포세이다 테라퓨틱스, 인크. |
동종이계 세포 조성물 및 사용 방법
|
CN114728049A
(zh)
|
2019-10-07 |
2022-07-08 |
再生生物股份有限公司 |
腺相关病毒载体药物组合物和方法
|
WO2021127505A1
(en)
|
2019-12-20 |
2021-06-24 |
Poseida Therapeutics, Inc. |
Anti-muc1 compositions and methods of use
|
KR20220149588A
(ko)
|
2020-03-04 |
2022-11-08 |
포세이다 테라퓨틱스, 인크. |
대사성 간 장애의 치료를 위한 조성물 및 방법
|
EP4118107A1
(de)
|
2020-03-11 |
2023-01-18 |
Poseida Therapeutics, Inc. |
Chimäre stimulationsrezeptoren und verfahren zur verwendung bei der t-zell-aktivierung und -differenzierung
|
CA3174777A1
(en)
|
2020-04-14 |
2021-10-21 |
Eric M. Ostertag |
Compositions and methods for use in the treatment of cancer
|
WO2021214588A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating coronavirus infections
|
WO2021214587A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating viral infections
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
IL301643A
(en)
|
2020-10-07 |
2023-05-01 |
Regenxbio Inc |
Gene therapy for ocular manifestations of CLN2 disease
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
EP4236974A2
(de)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vektorisierte faktor xii-antikörper und verabreichung davon
|
IL302282A
(en)
|
2020-10-29 |
2023-06-01 |
Regenxbio Inc |
Vectored TNF-alpha antagonists for ocular indications
|
US20240024507A1
(en)
|
2020-12-01 |
2024-01-25 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
WO2022182797A1
(en)
|
2021-02-23 |
2022-09-01 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
WO2022187671A1
(en)
|
2021-03-04 |
2022-09-09 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of hemophilia
|
EP4334334A1
(de)
|
2021-04-23 |
2024-03-13 |
The Trustees of The University of Pennsylvania |
Neue zusammensetzungen mit hirnspezifischen zielmotiven und zusammensetzungen damit
|
US20230040065A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
CN117957251A
(zh)
|
2021-07-09 |
2024-04-30 |
詹森生物科技公司 |
用于制备抗tnf抗体组合物的制造方法
|
TW202325845A
(zh)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
新穎aav衣殼及含其之組成物
|
AU2022360244A1
(en)
|
2021-10-04 |
2024-04-11 |
Poseida Therapeutics, Inc. |
Transposon compositions and methods of use thereof
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
WO2023164573A1
(en)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Genetically modified cells and methods of use thereof
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
WO2024036273A1
(en)
|
2022-08-11 |
2024-02-15 |
Poseida Therapeutics, Inc. |
Chimeric cd8-alpha co-receptor compositions and methods of use
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|